China's Alphamab Oncology raises $60m in Series B financing

Photo by Louis Reed on Unsplash

Chinese biopharmaceutical company Alphamab Oncology has raised $60 million in a Series B financing round, led by Hudson Bay Capital Management LP, a US and UK-based asset management firm.

The round was joined by new investors including entrepreneur Adrian Cheng, and existing institutional backers such as China Venture Capital Fund (CVC), Hong Kong-based private equity firm PAG, and VC firm Advantech Capital, according to an announcement.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter